[Evaluation of the efficiency of combined neuroprotection and high-intensity magnetotherapy in the medical rehabilitation of patients with ischemic stroke].

Butko DY, Davydov AT, Koneva ES, Lyadov KV, Okhotnikova AA, Reutsky IA, Shcheglova MA, Yakovlev EV

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2026

PMID42246531DOI10.17116/jnevro202612605188PepBankPUB-42246531

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, Cortexin (cortical polypeptide complex) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cortexin (cortical polypeptide complex).

01HumanNot a test of Cortexin (cortical polypeptide complex) aloneRandomized controlled trialEfficacy outcome
In stroke patients receiving Cortexin, Recognan and magnetic stimulation, the mean NIH Stroke Scale score at discharge was 9.3±0.2.
In plain wordsIn stroke patients receiving Cortexin, Recognan and magnetic stimulation, the average stroke severity score at discharge was 9.3.
Peptide
Cortexin (cortical polypeptide complex)
Outcome
Not applicableNIH Stroke Scale at discharge
Study
n = 34
Outcome group
Exercise and physical function · Nervous system and cognition
Measurements
NIH Stroke Scale
9.3 points
Group I at discharge
Source sentences
Summary
The mean score on the NIH Stroke Scale for Group I patients at discharge was 9.3±0.2 points, and the Rankin scale score was 2.1±0.2 points.
5 context sentences(design, population, supporting numbers)
Summary · context
This clinical study was a multicenter, prospective, observational, comparative, parallel-group study conducted in both public and private clinics as well as in rehabilitation facilities in St. Petersburg and Moscow.
Summary · context
Participants were randomized into three groups, each receiving standard therapy comprising exercise therapy, massage, and physiotherapy, as per established clinical guidelines.
Summary · context
Group I (n=34) also received Cortexin at a dosage of 10 mg intramuscularly twice daily for 15 days, and Recognan oral solution at 1000 mg, 10 ml, once daily for 21 days, along with high-intensity magnetic muscle stimulation.
Summary · context
Participants in Group II (n=33) received Cortexin at the same dosage and schedule, coupled with high-intensity magnetic muscle stimulation.
Summary · context
Group III (n=31) received no additional treatment.
In this study, Cortexin (cortical polypeptide complex) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cortexin (cortical polypeptide complex).
Report a problemFND-4224653110
02HumanNot a test of Cortexin (cortical polypeptide complex) aloneRandomized controlled trialEfficacy outcome
In stroke patients receiving Cortexin, Recognan and magnetic stimulation, the mean Rankin scale score at discharge was 2.1±0.2.
In plain wordsIn stroke patients receiving Cortexin, Recognan and magnetic stimulation, the average Rankin disability score at discharge was 2.1.
Peptide
Cortexin (cortical polypeptide complex)
Outcome
Not applicableRankin scale at discharge
Study
n = 34
Outcome group
Exercise and physical function · Nervous system and cognition
Measurements
Rankin scale
2.1 points
Group I at discharge
Source sentences
Summary
The mean score on the NIH Stroke Scale for Group I patients at discharge was 9.3±0.2 points, and the Rankin scale score was 2.1±0.2 points.
5 context sentences(design, population, supporting numbers)
Summary · context
This clinical study was a multicenter, prospective, observational, comparative, parallel-group study conducted in both public and private clinics as well as in rehabilitation facilities in St. Petersburg and Moscow.
Summary · context
Participants were randomized into three groups, each receiving standard therapy comprising exercise therapy, massage, and physiotherapy, as per established clinical guidelines.
Summary · context
Group I (n=34) also received Cortexin at a dosage of 10 mg intramuscularly twice daily for 15 days, and Recognan oral solution at 1000 mg, 10 ml, once daily for 21 days, along with high-intensity magnetic muscle stimulation.
Summary · context
Participants in Group II (n=33) received Cortexin at the same dosage and schedule, coupled with high-intensity magnetic muscle stimulation.
Summary · context
Group III (n=31) received no additional treatment.
In this study, Cortexin (cortical polypeptide complex) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cortexin (cortical polypeptide complex).
Report a problemFND-4224653111
03HumanNot a test of Cortexin (cortical polypeptide complex) aloneRandomized controlled trialEfficacy outcome
In patients with ischemic stroke, lower limb spasticity fell by 27% on day 14 with Cortexin, Recognan and magnetic stimulation, versus 15% with standard therapy alone.
In plain wordsIn stroke patients, Cortexin plus Recognan and magnetic stimulation reduced spasticity more than standard therapy alone.
Peptide
Cortexin (cortical polypeptide complex)
Outcome
DecreaseLower limb spasticity reduction at day 14 with triple regimen
Study
n: not reported in source
Comparator
standard therapy alone
Outcome group
Exercise and physical function · Nervous system and cognition
Measurements
Lower limb spasticity reduction
27%
Group I (Cortexin, Recognan and magnetic stimulation), day 14
Lower limb spasticity reduction
15%
Group III (standard therapy alone), day 14
Source sentences
Summary
In Group I, a 27% reduction in lower limb spasticity was noted on day 14, whereas Group II exhibited a 25% reduction, with Group III demonstrating a 15% reduction.
5 context sentences(design, population, supporting numbers)
Summary · context
This clinical study was a multicenter, prospective, observational, comparative, parallel-group study conducted in both public and private clinics as well as in rehabilitation facilities in St. Petersburg and Moscow.
Summary · context
Participants were randomized into three groups, each receiving standard therapy comprising exercise therapy, massage, and physiotherapy, as per established clinical guidelines.
Summary · context
Group I (n=34) also received Cortexin at a dosage of 10 mg intramuscularly twice daily for 15 days, and Recognan oral solution at 1000 mg, 10 ml, once daily for 21 days, along with high-intensity magnetic muscle stimulation.
Summary · context
Participants in Group II (n=33) received Cortexin at the same dosage and schedule, coupled with high-intensity magnetic muscle stimulation.
Summary · context
Group III (n=31) received no additional treatment.
In this study, Cortexin (cortical polypeptide complex) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cortexin (cortical polypeptide complex).
Report a problemFND-4224653101
04HumanNot a test of Cortexin (cortical polypeptide complex) aloneRandomized controlled trialEfficacy outcome
In patients with ischemic stroke, lower limb spasticity fell by 25% on day 14 with Cortexin plus magnetic stimulation, versus 15% with standard therapy alone.
In plain wordsIn stroke patients, Cortexin plus magnetic stimulation reduced spasticity more than standard therapy alone.
Peptide
Cortexin (cortical polypeptide complex)
Outcome
DecreaseLower limb spasticity reduction at day 14 with double regimen
Study
n: not reported in source
Comparator
standard therapy alone
Outcome group
Exercise and physical function · Nervous system and cognition
Measurements
Lower limb spasticity reduction
25%
Group II (Cortexin and magnetic stimulation), day 14
Lower limb spasticity reduction
15%
Group III (standard therapy alone), day 14
Source sentences
Summary
In Group I, a 27% reduction in lower limb spasticity was noted on day 14, whereas Group II exhibited a 25% reduction, with Group III demonstrating a 15% reduction.
5 context sentences(design, population, supporting numbers)
Summary · context
This clinical study was a multicenter, prospective, observational, comparative, parallel-group study conducted in both public and private clinics as well as in rehabilitation facilities in St. Petersburg and Moscow.
Summary · context
Participants were randomized into three groups, each receiving standard therapy comprising exercise therapy, massage, and physiotherapy, as per established clinical guidelines.
Summary · context
Group I (n=34) also received Cortexin at a dosage of 10 mg intramuscularly twice daily for 15 days, and Recognan oral solution at 1000 mg, 10 ml, once daily for 21 days, along with high-intensity magnetic muscle stimulation.
Summary · context
Participants in Group II (n=33) received Cortexin at the same dosage and schedule, coupled with high-intensity magnetic muscle stimulation.
Summary · context
Group III (n=31) received no additional treatment.
In this study, Cortexin (cortical polypeptide complex) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cortexin (cortical polypeptide complex).
Report a problemFND-4224653102
05HumanNot a test of Cortexin (cortical polypeptide complex) aloneRandomized controlled trialEfficacy outcome
In stroke patients, lower limb spasticity fell by 27% on day 14 with Cortexin, Recognan and magnetic stimulation, versus 25% with Cortexin and magnetic stimulation.
In plain wordsIn stroke patients, spasticity decreased more with Cortexin, Recognan and magnetic stimulation than with Cortexin and magnetic stimulation.
Peptide
Cortexin (cortical polypeptide complex)
Outcome
DecreaseLower limb spasticity reduction at day 14 between active regimens
Study
n: not reported in source
Comparator
Cortexin plus magnetic stimulation
Outcome group
Exercise and physical function · Nervous system and cognition
Measurements
Lower limb spasticity reduction
27%
Group I (Cortexin, Recognan and magnetic stimulation), day 14
Lower limb spasticity reduction
25%
Group II (Cortexin and magnetic stimulation), day 14
Source sentences
Summary
In Group I, a 27% reduction in lower limb spasticity was noted on day 14, whereas Group II exhibited a 25% reduction, with Group III demonstrating a 15% reduction.
5 context sentences(design, population, supporting numbers)
Summary · context
This clinical study was a multicenter, prospective, observational, comparative, parallel-group study conducted in both public and private clinics as well as in rehabilitation facilities in St. Petersburg and Moscow.
Summary · context
Participants were randomized into three groups, each receiving standard therapy comprising exercise therapy, massage, and physiotherapy, as per established clinical guidelines.
Summary · context
Group I (n=34) also received Cortexin at a dosage of 10 mg intramuscularly twice daily for 15 days, and Recognan oral solution at 1000 mg, 10 ml, once daily for 21 days, along with high-intensity magnetic muscle stimulation.
Summary · context
Participants in Group II (n=33) received Cortexin at the same dosage and schedule, coupled with high-intensity magnetic muscle stimulation.
Summary · context
Group III (n=31) received no additional treatment.
In this study, Cortexin (cortical polypeptide complex) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cortexin (cortical polypeptide complex).
Report a problemFND-4224653103
06HumanNot a test of Cortexin (cortical polypeptide complex) aloneRandomized controlled trialEfficacy outcome
In stroke patients, 52% of those receiving Cortexin, Recognan and magnetic stimulation showed increases in maximum and linear vertebral artery blood flow velocity, versus 20% with standard therapy.
In plain wordsIn stroke patients, more had faster vertebral artery blood flow with Cortexin, Recognan and magnetic stimulation (52%) than with standard therapy (20%).
Peptide
Cortexin (cortical polypeptide complex)
Outcome
IncreaseIncrease in maximum and linear vertebral artery blood flow velocity with triple regimen
Study
n: not reported in source
Comparator
standard therapy alone
Outcome group
Cerebral blood flow · Nervous system and cognition
Measurements
Patients with increased flow velocity
52%
Group I (Cortexin, Recognan and magnetic stimulation)
Patients with increased flow velocity
20%
Group III (standard therapy alone)
Source sentences
Summary
USDG data indicated that 52% of patients in Group I showed increases in maximum and linear blood flow velocity in both the right and left vertebral arteries after treatment, compared to 41% in Group II and 20% in Group III.
5 context sentences(design, population, supporting numbers)
Summary · context
This clinical study was a multicenter, prospective, observational, comparative, parallel-group study conducted in both public and private clinics as well as in rehabilitation facilities in St. Petersburg and Moscow.
Summary · context
Participants were randomized into three groups, each receiving standard therapy comprising exercise therapy, massage, and physiotherapy, as per established clinical guidelines.
Summary · context
Group I (n=34) also received Cortexin at a dosage of 10 mg intramuscularly twice daily for 15 days, and Recognan oral solution at 1000 mg, 10 ml, once daily for 21 days, along with high-intensity magnetic muscle stimulation.
Summary · context
Participants in Group II (n=33) received Cortexin at the same dosage and schedule, coupled with high-intensity magnetic muscle stimulation.
Summary · context
Group III (n=31) received no additional treatment.
In this study, Cortexin (cortical polypeptide complex) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cortexin (cortical polypeptide complex).
Report a problemFND-4224653104
07HumanNot a test of Cortexin (cortical polypeptide complex) aloneRandomized controlled trialEfficacy outcome
In stroke patients, 41% of those receiving Cortexin and magnetic stimulation showed increases in maximum and linear vertebral artery blood flow velocity, versus 20% with standard therapy.
In plain wordsIn stroke patients, more had faster vertebral artery blood flow with Cortexin and magnetic stimulation (41%) than with standard therapy (20%).
Peptide
Cortexin (cortical polypeptide complex)
Outcome
IncreaseIncrease in maximum and linear vertebral artery blood flow velocity with double regimen
Study
n: not reported in source
Comparator
standard therapy alone
Outcome group
Cerebral blood flow · Nervous system and cognition
Measurements
Patients with increased flow velocity
41%
Group II (Cortexin and magnetic stimulation)
Patients with increased flow velocity
20%
Group III (standard therapy alone)
Source sentences
Summary
USDG data indicated that 52% of patients in Group I showed increases in maximum and linear blood flow velocity in both the right and left vertebral arteries after treatment, compared to 41% in Group II and 20% in Group III.
5 context sentences(design, population, supporting numbers)
Summary · context
This clinical study was a multicenter, prospective, observational, comparative, parallel-group study conducted in both public and private clinics as well as in rehabilitation facilities in St. Petersburg and Moscow.
Summary · context
Participants were randomized into three groups, each receiving standard therapy comprising exercise therapy, massage, and physiotherapy, as per established clinical guidelines.
Summary · context
Group I (n=34) also received Cortexin at a dosage of 10 mg intramuscularly twice daily for 15 days, and Recognan oral solution at 1000 mg, 10 ml, once daily for 21 days, along with high-intensity magnetic muscle stimulation.
Summary · context
Participants in Group II (n=33) received Cortexin at the same dosage and schedule, coupled with high-intensity magnetic muscle stimulation.
Summary · context
Group III (n=31) received no additional treatment.
In this study, Cortexin (cortical polypeptide complex) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cortexin (cortical polypeptide complex).
Report a problemFND-4224653106
08HumanNot a test of Cortexin (cortical polypeptide complex) aloneRandomized controlled trialEfficacy outcome
In stroke patients, 52% receiving Cortexin, Recognan and magnetic stimulation showed increases in maximum and linear vertebral artery blood flow velocity, versus 41% with Cortexin and magnetic stimulation.
In plain wordsIn stroke patients, more had faster vertebral artery blood flow with Cortexin, Recognan and magnetic stimulation (52%) than with Cortexin and magnetic stimulation (41%).
Peptide
Cortexin (cortical polypeptide complex)
Outcome
IncreaseIncrease in maximum and linear vertebral artery blood flow velocity between active regimens
Study
n: not reported in source
Comparator
Cortexin plus magnetic stimulation
Outcome group
Cerebral blood flow · Nervous system and cognition
Measurements
Patients with increased flow velocity
52%
Group I (Cortexin, Recognan and magnetic stimulation)
Patients with increased flow velocity
41%
Group II (Cortexin and magnetic stimulation)
Source sentences
Summary
USDG data indicated that 52% of patients in Group I showed increases in maximum and linear blood flow velocity in both the right and left vertebral arteries after treatment, compared to 41% in Group II and 20% in Group III.
5 context sentences(design, population, supporting numbers)
Summary · context
This clinical study was a multicenter, prospective, observational, comparative, parallel-group study conducted in both public and private clinics as well as in rehabilitation facilities in St. Petersburg and Moscow.
Summary · context
Participants were randomized into three groups, each receiving standard therapy comprising exercise therapy, massage, and physiotherapy, as per established clinical guidelines.
Summary · context
Group I (n=34) also received Cortexin at a dosage of 10 mg intramuscularly twice daily for 15 days, and Recognan oral solution at 1000 mg, 10 ml, once daily for 21 days, along with high-intensity magnetic muscle stimulation.
Summary · context
Participants in Group II (n=33) received Cortexin at the same dosage and schedule, coupled with high-intensity magnetic muscle stimulation.
Summary · context
Group III (n=31) received no additional treatment.
In this study, Cortexin (cortical polypeptide complex) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cortexin (cortical polypeptide complex).
Report a problemFND-4224653108

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

[Evaluation of the efficiency of combined neuroprotection and high-intensity magnetotherapy in the medical rehabilitation of patients with ischemic stroke].

Summary

Results from this study8

Studies that did not test the peptide alone8

Version history

Subjects

Publication types

MeSH terms

Keywords